Medication info

Farime Duo Tablet 5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Ahn Gook Pharmaceutical Co., Ltd.
Appearance
Brownish yellow, oval, double convex film-coated tablet
Packaging
10 tablets/box [10 tablets/PTP X 1], 60 tablets/box [10 tablets/PTP X 6], 60 tablets/bottle
Approval status
Active

MFDS item code 202201359 · Approved 2022.04.04

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each active ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Ahn Gook Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Adult type 2 diabetes
  • poor blood sugar control
  • cardiovascular disease
View approved original text

This medication is used in combination with empagliflozin and metformin to assist blood sugar control in adults with type 2 diabetes during dietary and exercise therapy. It is particularly administered when blood sugar is not adequately controlled, and it can also be expected to be effective in patients with cardiovascular disease. However, for detailed information regarding the occurrence of cardiovascular events, reference should be made to clinical trial information for professionals. This medication helps improve blood sugar control.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each active ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication can cause a rare but serious side effect known as severe lactic acidosis, so it should not be administered to patients at high risk for lactic acidosis. Additionally, caution should be exercised when used in conjunction with insulin or sulfonylurea medications, as hypoglycemia may occur. Patients with moderate or severe renal impairment, acute kidney problems, severe infections, heart failure, acute myocardial infarction, and others should not use this medication. Before and after examinations using iodinated contrast agents, medication should be temporarily discontinued due to the risks of renal injury and lactic acidosis, and resumed only after renal function has returned to normal. It is recommended that pregnant or potentially pregnant women and nursing mothers do not use this medication. This medication is affected by renal function, therefore kidney function tests should be conducted regularly before and during administration. Patients at risk of fluid loss, for example, those with dehydration, diarrhea, or vomiting, should use this medication cautiously. If necessary, medication can be temporarily discontinued. This medication may cause side effects such as gastrointestinal disturbance, hypoglycemia, urinary tract infections, genital infections, increased urination, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, abnormal liver function tests, hepatitis, altered taste, itching, rash, erythema, edema, dysuria, thirst, increased serum lipids, increased serum creatinine, elevated hematocrit, decreased vitamin B12 and deficiency, vitamin D deficiency, headache, dizziness, drowsiness, insomnia, anxiety, fatigue, facial and peripheral edema, and cough. Particularly in elderly or frail patients, and those with poor nutritional status, caution is necessary due to the increased risk of hypoglycemia. Alcohol consumption can increase the risk of lactic acidosis, so excessive drinking should be avoided while taking this medication. Patients scheduled for surgery should discontinue this medication 48 hours prior to surgery and resume only after renal function has been confirmed to be normal post-surgery. During treatment, blood sugar control status should be regularly monitored, and any unusual symptoms should be reported to a healthcare professional immediately. This medication is not recommended for children under the age of 18, and in patients over 75 years of age, care should be taken to monitor fluid loss and renal function.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infections
  • perineal necrosis
  • vitamin B12 reduction and deficiency
  • ketoacidosis
  • lactic acidosis
Show 143 more
  • fluid volume reduction
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema and angioedema
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • intestinal hemorrhage
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • fecal incontinence
  • dry mouth
  • gastrointestinal disturbance
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • sensory impairment
  • orthostatic dizziness
  • dizziness
  • drowsiness
  • weakness
  • chest discomfort
  • chest pain
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • ligament injury
  • ligament sprain
  • arthralgia
  • lumbar pain
  • musculoskeletal pain
  • bone loss
  • urinary stones
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • anxiety
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • vulvar pruritus
  • genital pruritus
  • hyperglycemia
  • dyslipidemia
  • diabetes
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • rhegmatogenous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • skin laceration
  • rib fracture
  • iliotibial band syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is safest to keep it at room temperature between 1 and 30 degrees Celsius. Therefore, it is important to avoid direct sunlight and not to place it in excessively hot or cold environments.

Appearance and packaging

Appearance

Brownish yellow, oval, double convex film-coated tablet

Package unit

10 tablets/box [10 tablets/PTP X 1], 60 tablets/box [10 tablets/PTP X 6], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.